Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Performance Evaluation of LIVERFASt Tests to Determine Fibrosis Staging, Inflammatory Activity and Steatosis Grading Compared w/ Liver Biopsy in Patients w/ Metabolic Factors & Presumed Non-Alcoholic Fatty Liver Disease (NAFLD).

NCT04579874 is registered in ClinicalTrials.gov with Fibronostics USA, Inc as lead sponsor.

NCT NCT04579874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04579874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Performance Evaluation of LIVERFASt Tests to Determine Fibrosis Staging, Inflammatory Activity and Steatosis Grading Compared w/ Liver Biopsy in Patients w/ Metabolic Factors & Presumed Non-Alcoholic Fatty Liver Disease (NAFLD).
Lead sponsor
Fibronostics USA, Inc
Phase
Not applicable
Overall status
Completed
Start date
January 7, 2021
Completion date
April 15, 2022
Enrollment
241 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

liver fibroses, liver inflammation, liver steatoses, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis